Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 236-671-3 | CAS number: 13463-41-7
Neurotoxicity
Administrative data
Description of key information
Key value for chemical safety assessment
Effect on neurotoxicity: via oral route
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 25 mg/kg bw/day
Additional information
The information contained within this robust summary document comes from studies which are in the ownership of Arch Chemicals Inc. and which are protected in several regions globally. This information may not be used for any purpose other than in support of the Chemical safety Report submitted by Arch Chemicals Inc. under RegulationEC 1907/2006.
A guideline acute neurotoxicity with ZPT byBarnett (2005)under the U.S. Environmental Protection Agency (1998) Health Effects Test Guidelines; OPPTS 870.6200: Neurotoxicity screening battery, August, 1998.
On the basis of this study, the no-observable-adverse effect-level (NOAEL) of zinc pyrithione following a single dosage via oral gavage is 25 mg/kg. Changes observed at 25 mg/kg in body weights, feed consumption, and in females, motor activity, were minimal and transient.
A literature search in the open literature has revealed additional studies, which have shown that zinc pyrithione causes this neuropathy in both rats and rabbits. However, the hind limb weakness is reversible. In two studies with rats (Ziller 1977, Snyderet al.1977, following consumption of diet containing 250 ppm zinc pyrithione, animals lost this paralytic effect when returned to control diets.
When the Zinc pyrithione was tested in apes, Funato (1992), no signs of hind limb weakness was observed. Also, in repeated dermal toxicity studies,Ulrich (1993),and inhalation studies, Ulrich (1993), with the rat, no evidence of hind limb weakness was observed with any dose used.
Table 5.16: Summary of neurotoxicity
Method |
Results |
Remarks |
Reference |
Oral GavageRat Sprague Dawley.0, 25, 75, & 150 mg/kg Duration: 15 Days
|
LO(A)EL – 75 mg/kg NO(A)EL – 25 mg/kg There were no statistically significant or biologically important differences among the dosage groups for the hindlimb evaluations in the male or female rats. No test substance-related alterations were noted in the central or peripheral nervous system tissues, eyes with retinas and optic nerves, or skeletal muscle.
|
Reliability – 1 Purpose flag Study result type Test material: zinc pyrithione |
Barnett (2005) (unpublished) |
Justification for classification or non-classification
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
